From Edward Jenner's breakthrough discovery in 1796 that inoculating an eight-year-old boy with cowpox sores protected him against smallpox, the field of vaccinology has come a long way. Today, vaccine design often begins with researchers scouring the DNA sequences of pathogens to exhume buried targets that might trigger a robust immune response in people. Once identified, such targets become the focus of vaccine development. To be sure, most licensed vaccines are still manufactured by laboriously growing large batches of entire pathogens or their parts in vats of animal cells or chicken eggs, which serve as vaccine factories. But that approach is slowly yielding to genome-guided methods. For example, efforts to target the relatively unchanging stalk of a protein on the surface of the flu virus have energized the search for a universal flu vaccine in recent years. Such a vaccine would render moot the virus' notorious knack for evading the human immune system through constant mutation, and a handful of vaccine candidates are poised to enter clinical trials. Among the pioneers of the genome-guided approach to vaccine development is National Academy of Sciences member Rino Rappuoli, Chief Scientist at GlaxoSmithKline (GSK) Vaccines in Siena, Italy. At the 2016 Keystone Symposium on Translational Vaccinology for Global Health, Rappuoli traced the history of a new era in vaccine development that has come to be defined by undergirding advances in genetics and structural biology. Rappuoli spoke to PNAS about the long road to this new generation of vaccines.
PNAS: More than a decade ago, you coined the term "reverse vaccinology" to describe a nontraditional approach to vaccine design. Can you explain how the approach differs from conventional vaccine development?
Rappuoli: The concept of reverse vaccinology dates back to around 1996. From the beginning of vaccination's history, vaccines were made by growing pathogens and then either killing and injecting them or making live, attenuated versions of the pathogens for inoculation. The polio virus vaccines-the Salk and Sabin vaccines-are well-known examples of vaccines made in this way. The other way to make vaccines was by purifying components of pathogens that would elicit an immune response. All of these approaches meant that the pathogens had to be grown in the laboratory. In the mid-1990s, we realized that these classical approaches to vaccination were not working for one important pathogen, the meningococcus B bacterium, which accounts for almost half of all known cases of meningitis. There are five serogroups of the bacterium Neisseria meningitidis, and we were well on our way toward conjugate vaccines for all serogroups but B using the traditional approach. This approach relied on a sugar capsule that surrounds the bacterium. But the structural similarity of the serogroup B's sugar coat to a polysaccharide found in human tissues meant that we could not use our traditional approach for serogroup B.
PNAS: So you developed a "reverse" vaccine that has become something of a poster-child for genomeguided vaccine design. How was it designed?
Rappuoli: Around this time, Craig Venter (1) published the complete genome sequence of a bacterium in Science magazine, and that led to the thinking that instead of purifying components of pathogens grown in the laboratory, we might begin with the genome sequence of the pathogens and produce the components of interest. I asked Venter whether he would be willing to sequence the genome of meningococcus B, and we started a collaboration. This was the first time that a vaccine was made by beginning with information in a computer rather than with pathogens grown in the laboratory. So we termed this backward approach "reverse vaccinology." PNAS: How long did it take for the vaccine to be licensed?
Rappuoli: We began the project in 1996, and by 2000 we had sequenced the bacterial genome and identified the candidate antigens that we wanted to focus on. We published the findings in Science (2). For the next 13 years, we did all of the work to translate the findings into a product for the market. In 2013, the vaccine was approved by the European Medicines Agency, as well as in Canada and Australia. The US Food and Drug Administration approval followed in 2015, with a designation of breakthrough therapy.
PNAS: When the vaccine was launched, it was not readily embraced by health economists in the United Kingdom. What were the reasons behind the initial skepticism and eventual acceptance?
Rappuoli: Meningococcal disease has a high incidence in the United Kingdom, and there was a lot of awareness about the severity and toll of the disease among parents, pediatricians, as well as Public Health England [a government agency tasked with evaluating the cost-effectiveness of new drugs and vaccines to safeguard public health]. Despite its severity, the disease is rare, compared with many other childhood illnesses. So the UK's Joint Committee on Vaccination and Immunization, another government group that includes health economists, determined that the vaccine was not cost-effective at any price. But there was a lot of outcry from advocates, including parents of affected children, arguing that the committee's initial conclusion was flawed. A year later, the same committee revised their recommendation, saying that when all factors were considered, the vaccine was cost-effective at a low price. That recommendation served as the basis for the government's decision to give the vaccine to newborn children in the United Kingdom. In October 2016, almost a year after the vaccine began to be administered to newborn children, Public Health England published a report in The Lancet showing greater than 80% effectiveness against the disease in vaccinated individuals in the UK (3).
PNAS:
In your talk, you described a new generation of techniques that have together ushered in yet another era in vaccine development: reverse vaccinology 2.0, as it were. Can you describe some of these advances?
Rappuoli: Today, genome sequencing has advanced exponentially, compared with the 1990s. Today's reverse vaccinology approach involves sequencing dozens of strains of the same species of organism obtained from a range of habitats worldwide to represent the vast diversity of antigens that could inform vaccine development. Also, proteomics methods allow us to characterize the entire range of proteins expressed by a pathogen of interest. Moreover, 20 years ago, determining the structure of proteins was an arduous and time-consuming task; today, we can determine the structure of a large number of antigens using highthroughput, high-resolution analytical techniques. The other major advance in biotechnology is our ability to isolate human monoclonal antibodies from protected, immune people in a high-throughput fashion. Together, these advances have the potential to yet again change the pace of vaccine development.
PNAS: Structural biology, for example, has enabled rapid strides toward a universal flu vaccine, and several tantalizing preclinical findings have been published. From your perch at the helm of one of the world's foremost pharmaceutical companies, do these efforts hold promise?
Rappuoli: In the case of influenza, we can look in people who have had the flu for antibodies to both circulating and past strains of the virus. It turns out that these socalled broadly neutralizing antibodies recognize a portion of the hemagluttinin (HA) antigen on the flu virus that was previously considered unimportant for vaccine development. Subsequently, X-ray crystallography of this portion, called the stem region, and the monoclonal antibodies that bind to it, revealed important structural clues for vaccine development. Now the focus is on antibodies that target the antigen's stem. That said, the studies in this area are still mostly in the preclinical stage: more specifically, at the stage where the immunogens are being designed, with the hope of launching clinical trials in the next couple of years. Those trials will prove whether the approach based on the HA stem is a viable one.
Although childhood vaccines no doubt play vital roles in safeguarding public health, vaccines for the elderly have not received nearly the same attention. Do elderly populations represent an area of unmet medical need from the perspective of vaccine development?
Rappuoli: Only recently have people begun to think about the usefulness of vaccines for the elderly. When people age, they may become susceptible to diseases against which they were once vaccinated, such as tetanus, pertussis, meningococcus, pneumococcus etc. So in an aging society we may have to explore the need for conventional vaccines for the elderly. Another growing concern among elderly populations is infections due to increasing antimicrobial resistance, particularly hospital-acquired infections. That's another area of unmet medical need where reverse vaccinology 2.0 might play a crucial role. Finally, it is not far-fetched to envision a future in which cancer vaccines are used to delay or perhaps prevent the onset of cancer in aging populations, complementary to the current focus on treatments and cures.
Until recently, the thinking has been that vaccines are not very efficacious at preventing disease in the elderly because of their relatively weakened immune responses. The influenza vaccine is often cited as an example. But our recent studies with the recombinant herpes zoster vaccine have shown, for example, that administering the vaccine with the AS01 adjuvant can help maintain its efficacy even in 90-year-old individuals (4).
The reactive approach to vaccine development for emerging infectious diseases is now widely recognized as an impediment to pandemic readiness and has spurred prominent initiatives, such as the Coalition for Epidemic Preparedness Innovations (CEPI), a public-private alliance funded by the Wellcome Trust and the Bill and Melinda Gates Foundation to fund early-stage trials of neglected vaccine candidates. The Ebola vaccine is a familiar case in point; by the time the vaccine tests got under way, the epidemic had begun to wane. Are you involved in CEPI or similar initiatives?
Rappuoli: Already around 1999, there was enough data to make a vaccine for Ebola, but because it was not cost-effective back then, there was no push to manufacture and test it. The epidemic that ensued was a global wake-up call. There were a handful of experts who convened at the World Economic Forum in Davos at the beginning of 2016 to address the need for preparedness for emerging epidemics.
CEPI was one initiative that resulted from this meeting and is poised to make inroads toward the goal. But there are a handful of other such initiatives. At GSK, for example, we made a similar proposal to partner with the public sector and create a biopreparedness organization (BPO), in which we would contribute our know-how and resources for targets selected by the public sector on a no-cost/no-loss basis (and the public sector would assume the running costs of such an organization). Talks are ongoing to determine whether CEPI and BPO should be merged, and deliberations are likely to happen in Davos early next year. The hope is that we can get commitments from various governments for such a combined initiative.
